JPH0342276B2 - - Google Patents
Info
- Publication number
- JPH0342276B2 JPH0342276B2 JP58050590A JP5059083A JPH0342276B2 JP H0342276 B2 JPH0342276 B2 JP H0342276B2 JP 58050590 A JP58050590 A JP 58050590A JP 5059083 A JP5059083 A JP 5059083A JP H0342276 B2 JPH0342276 B2 JP H0342276B2
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- group
- formula
- bonded
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003874 central nervous system depressant Substances 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- -1 alkyl isocyanate Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000005059 halophenyl group Chemical group 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical group NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000005792 cardiovascular activity Effects 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000003997 cyclic ketones Chemical class 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 1
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical compound NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- FNXYWHTZDAVRTB-UHFFFAOYSA-N 3-methyl-1,2-oxazol-5-amine Chemical compound CC=1C=C(N)ON=1 FNXYWHTZDAVRTB-UHFFFAOYSA-N 0.000 description 1
- HSGVZNCMBXGDTD-UHFFFAOYSA-N 4-(cyclohexen-1-yl)-3-methyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1C1=CCCCC1 HSGVZNCMBXGDTD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ULUYTIIQLDEZJL-UHFFFAOYSA-N isoquinoline;1,2-oxazole Chemical class C=1C=NOC=1.C1=NC=CC2=CC=CC=C21 ULUYTIIQLDEZJL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
æ¬çºæã¯åŒ
ãåŒäžãã¯ççŽ æ°ãïŒãïŒã®äœçŽã¢ã«ãã«ãŸ
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ R1ïŒR2ã¯ã¢ã«ãã¬ã³åºâïŒCH2ïŒoâãè¡šããã
ããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããããããŠãããã®
ã¡ãã¬ã³åºã®ïŒã€ã¯åº
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ R1ïŒR2ã¯ã¢ã«ãã¬ã³åºâïŒCH2ïŒoâãè¡šããã
ããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããããããŠãããã®
ã¡ãã¬ã³åºã®ïŒã€ã¯åº
ãåŒãã«ãã眮ãæã
ãããŠããŠããããããã§R6ã¯äœçŽã¢ã«ãã«ã
äœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢ã«ã³ãã·ïŒã«ã«
ããã«ãè¡šããïŒR3ã¯ïŒåã ãååšããŠããã
ããŠæ°ŽçŽ ãäœçŽã¢ã«ãã«ãããããã·âäœçŽã¢ã«
ãã«ããã³ãžã«ãè¡šããããããŠãããè€çŽ ç°åŒ
çªçŽ ãšçµåããŠããå Žåã«ã¯ããã®ã¢ãã³çªçŽ ã
ãžã¢ã«ãã«çœ®æãããŠããŠããããããã¯é£œåè€
çŽ ç°åŒç°äžã«å å«ãããŠããŠããããããŒäœçŽã¢
ã«ãã«ãŸãã¯ã¢ããâäœçŽã¢ã«ãã«ããè¡šããïŒ ç¹ç·ã¯äºéçµåãè€çŽ ç°åŒçªçŽ ååãšççŽ åå
ãšã®éãŸãã¯é žçŽ ãšççŽ ååãšã®éã®ããããã«
ååšããŠããããšã瀺ããŠããã第äžã®å Žåã«ã¯
åºR3ã¯é žçŽ ãšçµåããŠããã第äºã®å Žåã«ã¯çª
çŽ ååãšçµåããŠããã ã®æ°èŠãªã€ãœããµãŸãŒã«ãïŒïŒïŒâïœãããªãžã³
é¡ã«é¢ãããã®ã§ããã ããã§äœ¿çšãããŠããâäœçŽã¢ã«ãã«âãšãã
èªã¯ãçŽéãããã¯åæéç¶ã®ïŒC1ãC6ïŒã¢ã«
ãã«åºãäŸãã°ã¡ãã«ããšãã«ããããã«ãã€ãœ
ãããã«ãïœâããã«ãã»ã«ã³ããªãŒâããã«ã
ã¿ãŒã·ã€ãªãŒâããã«ãªã©ããè¡šãããâäœçŽã¢
ã«ã³ãã·âãšããèªã¯ãçŽéãããã¯åæéç¶ã®
ïŒC1ãC6ïŒã¢ã«ã³ãã·åºãäŸãã°ã¡ããã·ããšã
ãã·ãããããã·ãã€ãœâããããã·ãïœâãã
ãã·ãïœâãããã·ãªã©ã©ãè¡šãããâäœçŽã¢ã«
ã«ãã€ã«âãšããèªã¯çŽéãããã¯åæéç¶ã®
ïŒC1ãC6ïŒã¢ã«ã«ãã€ã«åºãäŸãã°ã¢ã»ãã«ãã
ãããã€ã«ããã¿ãã€ã«ãªã©ããè¡šããã æ¬çºæã®ååç©é¡ã䞊ã³ã«ä»¥äžã«èšãããŠãã
ãããã®åæçšã®å€ãã®äžéçæç©é¡ã¯æççã
å¿èè¡ç®¡åã³CNSæå¶æŽ»æ§ãæããã æ¬çºæã®ååç©ã補é ããããã®äžè¬çæ¹æ³ã¯
ïŒâ眮æãããïŒâã¢ããã€ãœããµãŸãŒã«ãã
åºçºãã該æ¹æ³ã§ã¯ãããç°åŒã±ãã³ãšåå¿ã
ããŠïŒïŒïŒâãžçœ®æãããïŒâã¢ããã€ãœããµãŸ
ãŒã«ãçæããã ãããã®åŒäžãïŒR1åã³R2ã¯äžèšã®æå³ã
æãããåå¿ã¯æº¶åªãšããŠã®äœçŽã«ã«ãã³é žã奜
é©ã«ã¯é ¢é žãäžã§ã宀枩ãšæº¶åªã®æ²žéš°æž©åºŠãšã®é
ã®æž©åºŠç¯å²ã«ãããŠã奜é©ã«ã¯40ã70âã«ãã
ãŠãæè¯ã«å®æœããããïŒçš®ã®åå¿ç©éã®ã¢ã«æ¯
ã¯åå¿ç©ã®æ§è³ªã«ããå€åãããæ®éïŒã¢ã«ã®ã€
ãœããµãŸãŒã«åœãïŒã¢ã«ããéå°ãªïŒã¢ã«ãŸã§ã®
ç°åŒã±ãã³ãè¯å¥œãªçµæãäžãããåå¿æéã¯åº
ãç¯å²å ã§å€åããããã¯å€§éšå䜿çšæž©åºŠã«äŸå
ããŠãããããå Žåã«ã¯å®å šãªåå¿ãåŸãã«ã¯ïŒ
ãïŒæéã§å åã§ããããããå Žåã«ã¯24ã36æ
éãé©åœã§ããã ååç©ããäœçŽã¢ã«ãã«ã€ãœã·ã¢ããŒãã§åŠ
çãããšãã€ãœããµãŸãŒã«ãïŒïŒïŒâïœãâããª
ãã³ïŒ¶ãäžãããããã¢ã«ã«ãªæ°ŽçŽ åç©åã³æ¬¡ã«
ã¢ã«ãã«åå€ã§åŠçãããšãâåã³ïŒ®â眮æã
ããã€ãœããµãŸãâãïŒïŒïŒâïœãâããªãžã³é¡
åã³ãäžããã ãããã®å šãŠã®åŒäžãïŒR1åã³R2ã¯äžèšã®
æå³ãæããããããšã¯å¯Ÿç §çã«ãR3ã¯æ°ŽçŽ ã
äœçŽã¢ã«ãã«ãããããã·âäœçŽã¢ã«ãã«åã³ã
ã³ãžã«ã ããè¡šãããã®ãžã®è»¢åã¯ã溶åªãš
ããŠäŸãã°ããªãšãã«ã¢ãã³ãŸãã¯ããªãžã³ã®åŠ
ã第äžçŽå¡©åºã䜿çšããŠãäœçŽã¢ã«ãã«ã€ãœã·
ã¢ããŒããšå ±ã«æº¶åªã®æ²žéš°æž©åºŠã«ãããŠïŒãïŒæ
éã«ãã€ãŠå ç±ããããšã«ããæè¯ã«å®æœãã
ããäžéçæç©ã§ããå°¿çŽ ãåå¿äžã«çæãã
ããåŸã ã«ããã¯ãé«åçã§äžããã ãåã³ã®æ··åç©ã«è»¢åãããããã«ã¯ã
ååç©ãæåã«ç¡æ°Žæº¶åªäžã§æ°ŽçŽ åãããªãŠã
ã§åŠçããŠãããªãŠã å¡©ãåŸãŠããããåã溶åª
äžã§ã40ã80âã«ïŒãïŒæéå ç±ãããååç©
åã³ãåå¿æ¡ä»¶ã«ããå¯å€æ§ã§ããçžäºæ¯ã§ç
æãããå Žåæ¯ã«æé©ãªåå¿æ¡ä»¶ãéžæããããš
ã«ãããåå¿ããŸãã¯ã®å¥œãŸããçææ¹åã«
åããããšã倧äœå¯èœã§ããã R3ããããŒäœçŽã¢ã«ãã«ãŸãã¯ã¢ããâäœçŽ
ã¢ã«ãã«ãæå³ããããã§ã¢ããçªçŽ ããžã¢ã«ã
ã«çœ®æãããŠããŠããããŸãã¯é£œåè€çŽ ç°åŒç°äž
ã«å«ãŸããŠããŠããããããªåŒã®ååç©ãåžæ
ãããšãã«ã¯ãR3ãããããã·âäœçŽã¢ã«ãã«
ãæå³ããäžèšãããã¯ååç©ãŸãã¯ããã
ã®æ··åç©ãæåã«å¯Ÿå¿ãããããŒäœçŽã¢ã«ãã«èª
å°äœã«è»¢åãããããŠãããã®åŸè ã¯åœæè¡ã®å š
ãŠã®å°é家ã«è¯ãç¥ãããŠããæ¹æ³ã«ããã¢ãã
âäœçŽã¢ã«ãã«èªå°äœã«è»¢åãããããã®åå¿æ®µ
éã®åºçºååç©ãšããŠã®ååç©ã®äœ¿çšã¯ãç°åŒ
äžéçæç©ã®çæã«ããé žçŽ ããçªçŽ ååãžã®ã¯
ããâäœçŽã¢ã«ãã«åºã®è»¢äœãå å«ããŠããã ãããã®å Žåã«ãããã«ããæçµååç©ã¯è€çŽ
ç°åŒçªçŽ ååãšçµåãããŠãã眮æåºR3ãæã
ããå®éçã«ã¯ãR3ãããããã·âäœçŽã¢ã«ã
ã«åºã§ããååç©ãããã¯ååç©ãŸãã¯ãã
ãã®æ··åç©é¡ãäŸãã°C1ãC4ããã²ã³åçåæ°Ž
çŽ ã®åŠãé©åœãªææ©æº¶åªäžã«æº¶è§£ãŸãã¯æžæ¿ã
ãããããŠïŒã¢ã«ããéå°éã®ã奜é©ã«ã¯çŽïŒã
çŽïŒã¢ã«åœéã®ãããã²ã³åå€ãå ãããå®è³ªç
ã«å šãŠã®äžè¬çããã²ã³åå€ã¯æºè¶³ã®ããããã«
äœçšããããããã²ã³åããªãã«ãäŸãã°å¡©åã
ãªãã«ãŸãã¯èåããªãã«ãã宀枩ãšçŽ70âãšã®
éã®ç¯å²å ã®äœçŽã§äœ¿çšããããšã«ããæè¯ã®çµ
æãæ®éåŸããããããŠããã¯ïŒãïŒæéå ã«å®
äºããã 次ã«ã¢ããâäœçŽã¢ã«ãã«èªå°äœé¡ãæçœãªå·¥
çšã«ãããäŸãã°ã¯ããã¢ã«ãã«èªå°äœãåœæè¡
ã®å šãŠã®å°é家ã«ãšã€ãŠäžè¬çã«å ¬ç¥ã§ãããã
ãŠå®æœäŸããæçœã§ããæ¡ä»¶äžã§ãå¡©åºã§åŠçã
ãããšã«ããã補é ãããäžèšã®åŠããæ¬çºæã®
ååç©é¡ã¯èå³ããCNSâæå¶ãæäžå®åã³æ
çç掻æ§ãæãããããã«ããããã¯äžè¬ã«ãã
ã®LD50å€ãããã«ããºããžã®è ¹è å æäžæã«ã¯
500mgïŒKgããé«ããããŠçµå£çæäžæã«ã¯ãã€
ãã«1000mgïŒKgããäœããªãããçžåœäœãæ¯æ§ã
æãããæçç掻æ§ã¯ããºãäžã§ã®âã«ã©ã²ãšã
ã³èªçºæ§æµ®è «è©Šéšâã«ãã確ãããããããã®ã
ããªè©Šéšã¯C.A.ãŠã€ã³ã¿ãŒïŒWinterïŒä»èã
Proc.Soc.Exptl.Biol.Med.111ïŒ544ïŒ1962ã«ãã
æå±ãããŠããæäœåŒã«åŸã€ãŠè¡ãªããããããŠ
å®æœäŸ5aïŒ21ïŒ22åã³24ã®ååç©é¡ïŒïŒ®âç°æ§
äœé¡ïŒã®LD50å€ã®çŽ1/5ãçŽ1/10ã®éã®çµå£æäž
éãå¯Ÿç §çšã«æ¯ã¹ãŠ35ïŒ ä»¥äžã®æµ®è «ã®çžåœãªæžå°
ãçãåŸããšããããšãèŠåºãããã CNSâæå¶æŽ»æ§ã¯S.ã¢ãŒãŠã€ã³ïŒIrwinïŒèã
PsychopharmacologiaïŒBarl.ïŒ13ïŒ222â257ïŒ
1968äžã«èšãããŠããåŠãäžè¬ç粟ç¥ç©çåŠçäº
æ€æ¹æ³ã«ããè©Šéšããããç¹ã«ãããã«ããºãã«
察ããŠå®æœãããããã€ãã®ä»£è¡šçå®éšã¯ãçŽïŒ
ãçŽ100mgïŒKgè ¹è å ã®ååç©ã®éãç¬éç掻æ§
åã³çèç·åŒµã®æå¶ã«æå¹ã§ããããçŽ30ãçŽ
300mgïŒKgè ¹è å ã®éã¯ç 究宀åç©ã®éåå ±èª¿å
ã³æ£ååå°ãçžåœæãªãããšã瀺ããŠããã äžèšã®èŠçŽ ãçŽæ¥é®æãå¬ç åã³çåŒç·©ã«é¢é£
ããŠããããšã«æ³šæãã¹ãã§ãããæ¬çºæã®åå
ç©ã®æäžå®æŽ»æ§ã¯G.ãããã€ïŒMaffiiïŒèã
Journ.Pharm.Pharmacol.11ïŒ129ïŒ1959äžã«èš
èŒãããŠããåŠãããŠå®æœããããâæ±ç»ãåé¿
è©Šéšâã«ããè©Šéšãããããã§ã¯æ¡ä»¶ã¥ãåç©
ïŒäžè¬ã«ããºãïŒãæ¡ä»¶è§£é€ãããªãã¡é©åœéã®
è©Šéšããããšããååç©ã®æäžã«ããããã®éåžž
ã®ç²Ÿç¥è¡åã«ããããG.ãããã€ã«åŸããšãäž»
æ¡ä»¶ã¥ãå¿çïŒCRïŒãšæ¡ä»¶ã¥ããããŠããªãå¿
çïŒURïŒã®åææå¶ãªãã®ãããªãã¡äž»æ¡ä»¶ã¥
ãå¿çãšæ¡ä»¶ã¥ããããŠããªãå¿çïŒURïŒã®æ
å³ã®ãªãæå¶ãšçµåããå¯æ¡ä»¶ã¥ãå¿çïŒCR1ïŒ
ã®æå¶ã¯æäžå®å¹æã®æçœãªæ瀺ã§ããããã®ç
ç±ã¯ãããã®æåŸã®ïŒåã®èŠçŽ ã¯é®éåã³å¬ç æ§
ã«é¢é£ããŠããããã§ããã 10å¹ã®ããºã矀ã«å¯ŸããŠå®æœããã代衚çå®éš
ã¯ãå®æœäŸ1bïŒ4aïŒ12aïŒ25ïŒïœâç°æ§äœïŒåã³
41ïŒïœâç°æ§äœïŒã®ååç©é¡ã®çŽ15ãçŽ60mgïŒKg
ã®äœéã«å€åããè ¹è å æäžãããæäžéã¯CR2
âèŠçŽ ã®æå¶ã«éåžžã«æå¹ã§ãããããŠåæã«
CRåã³URã«å¯ŸããŠå®éçã«åœ±é¿ãæããªãã
ãšã瀺ããŠããã æ¬çºæã®ååç©é¡ã¯ç°ãªãçµè·¯ã«ããæäžã§ã
ãã奜é©ãªæäžçµè·¯ã¯çµå£çåã³çŽè žå æäžã§
ããéçµå£æäžã䜿çšã§ãããçµå£çæäžçšã«
ã¯ãååç©é¡ã補è¬åŠçæäžåœ¢ãäŸãã°é å€ãã«
ãã»ã«ããšãªãã·ã«ã溶液ãªã©ãã«ãããæäžå
äœã¯æ®éã®è³Šåœ¢è¬ãäŸãã°ã§ãã·ãããŽã ãèèª
é žé¡ãã¢ã«ã³ãŒã«é¡ãç³é¡ãªã©ããå«æã§ããã
çŽè žå æäžçšã«ã¯ãååç©é¡ã¯äžè¬ç賊圢è¬ãäŸ
ãã°ã³ã³ã¢ãã¿ãŒãã¯ãã¯ã¹ã鯚ãããŸãã¯ããª
ãªãã·ãšãã¬ã³ã°ãªã³ãŒã«é¡åã³ãããã®èªå°äœ
é¡ããšæ··åãããåè¬ã®åœ¢ã§æäžãããã æäžéç¯å²ã¯ïŒæ¥åœãçŽ0.05ãçŽ200ïœã§ããã
ããã¯å¥œé©ã«ã¯åå²æäžã§æäžãããã åŸã€ãŠãæ¬çºæã¯æŽ»æ§æåãšããŠã®æ¬çºæã®å
åç©ã補è¬åŠçã«èªå®¹ã§ããæ äœãšäžç·ã«å«æã
ãŠããæ²»ççšçµæç©ãæäŸãããã®ã§ããã äžèšã®è¿œå èšèŒåã³å®æœäŸã¯ããã«æ¬çºæã説
æãããã®ã§ãããããŠããã®è£œé åã³äœ¿çšæ¹æ³
ã¯åœæè¡ã®å°é家ãå®è¡ã§ãããã®ã§ããã以äž
ã«æ¬çºæãå®æœããããã®çºæè çã«ããæå³ã
ããæè¯ã®åœ¢æ ã瀺ãã å®æœäŸ ïŒ ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«ã€
ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³â
ïŒïŒïŒšïŒâãªã³ ïœïŒ ïŒâã¢ããâïŒâã¡ãã«ã€ãœããµãŸãŒã«
ïŒ17ïœïŒã®é ¢é žïŒ170mlïŒäžæº¶æ¶²ã«35mlã®ã·ã¯ã
ãããµãã³ãå ãããããŠæ··åç©ã70âã«17æ
éå ç±ãããé ¢é žãç空äžã§èžçé€å»ããæ®æž£
ãé ¢é žãšãã«äžã«æº¶è§£ããã溶液ãçé žæ°ŽçŽ ã
ããªãŠã ã®é£œå氎溶液åã³æ¬¡ã«æ°Žã§æŽæµããç¡
æ°Žç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããããŠèžçºä¹Ÿåºã
ããç²è£œçæç©ããã®ãŸãŸæ¬¡ã®æ®µéçšã«äœ¿çšã§
ãããããã¯SiO2äžã®ã¯ãããã°ã©ãã€åã³
ïœâãããµã³ïŒé ¢é žãšãã«ã®ïŒïŒïŒæ··åç©ãçš
ãã溶åºã«ããåŸããããåé26ïœïŒ84ïŒ ïŒã®
ïŒâïŒïŒâã·ã¯ãããã»ã³âïŒâã€ã«ïŒâïŒâã¡
ãã«âïŒâã€ãœããµãŸãŒã«ã¢ãã³ïŒãžãšãã«ãš
ãŒãã«ããïŒãèç¹48âã ïœïŒ ç²è£œïŒâïŒïŒâã·ã¯ãããã»ã³âïŒâã€ã«ïŒ
âïŒâã¡ãã«âïŒâã€ãœããµãŸãŒã«ã¢ãã³
ïŒ9.5ïœïŒã95mlã®ããªãžã³åã³15.8mlã®ãšãã«
ã€ãœã·ã¢ããŒãã®æ··åç©ãïŒæééæµããã次
ã«æº¶åªãç空äžã§èžçé€å»ãããæ®æž£ãïŒãïŒ
mlã®é ¢é žãšãã«ãšå ±ã«æ°åééæµããããããŠ
çæããçŽç²ãªïŒïŒïŒïŒïŒïŒïŒâããã©ããã
âïŒâã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâ
ã€ãœãããªã³âïŒïŒ4HïŒâãªã³ããã€ã«ã¿ãŒäž
ã§éãããããŠä¹Ÿç¥ããããžã¡ãã«ãã«ã ã¢ã
ãïŒã¡ã¿ããŒã«ããã®åçµæ¶ååŸã«ãçæç©ã¯
èç¹255âãæããŠãããçŽç²ãªäžéçæç©ã
ãåºçºãããšãã«ã¯ãäžéçæç©ã«å¯ŸããŠèšç®
ããŠ88ã92ïŒ ã®åçãåŸãããã å®æœäŸ ïŒã14 ïœïŒ ã€ãœããµãŸãŒã«ã¢ãã³é¡ åŒã®ãªããµãŸãŒã«ã¢ãã³åã³åŒã®ã±ãã³ã
ãåºçºãããšãå®æœäŸ1aïŒã«èšãããŠããæ¹æ³
ãšå®è³ªçã«åäžã®æ¹æ³ã«ããäžèšã®åŒã®ååç©
é¡ã補é ãããã
äœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢ã«ã³ãã·ïŒã«ã«
ããã«ãè¡šããïŒR3ã¯ïŒåã ãååšããŠããã
ããŠæ°ŽçŽ ãäœçŽã¢ã«ãã«ãããããã·âäœçŽã¢ã«
ãã«ããã³ãžã«ãè¡šããããããŠãããè€çŽ ç°åŒ
çªçŽ ãšçµåããŠããå Žåã«ã¯ããã®ã¢ãã³çªçŽ ã
ãžã¢ã«ãã«çœ®æãããŠããŠããããããã¯é£œåè€
çŽ ç°åŒç°äžã«å å«ãããŠããŠããããããŒäœçŽã¢
ã«ãã«ãŸãã¯ã¢ããâäœçŽã¢ã«ãã«ããè¡šããïŒ ç¹ç·ã¯äºéçµåãè€çŽ ç°åŒçªçŽ ååãšççŽ åå
ãšã®éãŸãã¯é žçŽ ãšççŽ ååãšã®éã®ããããã«
ååšããŠããããšã瀺ããŠããã第äžã®å Žåã«ã¯
åºR3ã¯é žçŽ ãšçµåããŠããã第äºã®å Žåã«ã¯çª
çŽ ååãšçµåããŠããã ã®æ°èŠãªã€ãœããµãŸãŒã«ãïŒïŒïŒâïœãããªãžã³
é¡ã«é¢ãããã®ã§ããã ããã§äœ¿çšãããŠããâäœçŽã¢ã«ãã«âãšãã
èªã¯ãçŽéãããã¯åæéç¶ã®ïŒC1ãC6ïŒã¢ã«
ãã«åºãäŸãã°ã¡ãã«ããšãã«ããããã«ãã€ãœ
ãããã«ãïœâããã«ãã»ã«ã³ããªãŒâããã«ã
ã¿ãŒã·ã€ãªãŒâããã«ãªã©ããè¡šãããâäœçŽã¢
ã«ã³ãã·âãšããèªã¯ãçŽéãããã¯åæéç¶ã®
ïŒC1ãC6ïŒã¢ã«ã³ãã·åºãäŸãã°ã¡ããã·ããšã
ãã·ãããããã·ãã€ãœâããããã·ãïœâãã
ãã·ãïœâãããã·ãªã©ã©ãè¡šãããâäœçŽã¢ã«
ã«ãã€ã«âãšããèªã¯çŽéãããã¯åæéç¶ã®
ïŒC1ãC6ïŒã¢ã«ã«ãã€ã«åºãäŸãã°ã¢ã»ãã«ãã
ãããã€ã«ããã¿ãã€ã«ãªã©ããè¡šããã æ¬çºæã®ååç©é¡ã䞊ã³ã«ä»¥äžã«èšãããŠãã
ãããã®åæçšã®å€ãã®äžéçæç©é¡ã¯æççã
å¿èè¡ç®¡åã³CNSæå¶æŽ»æ§ãæããã æ¬çºæã®ååç©ã補é ããããã®äžè¬çæ¹æ³ã¯
ïŒâ眮æãããïŒâã¢ããã€ãœããµãŸãŒã«ãã
åºçºãã該æ¹æ³ã§ã¯ãããç°åŒã±ãã³ãšåå¿ã
ããŠïŒïŒïŒâãžçœ®æãããïŒâã¢ããã€ãœããµãŸ
ãŒã«ãçæããã ãããã®åŒäžãïŒR1åã³R2ã¯äžèšã®æå³ã
æãããåå¿ã¯æº¶åªãšããŠã®äœçŽã«ã«ãã³é žã奜
é©ã«ã¯é ¢é žãäžã§ã宀枩ãšæº¶åªã®æ²žéš°æž©åºŠãšã®é
ã®æž©åºŠç¯å²ã«ãããŠã奜é©ã«ã¯40ã70âã«ãã
ãŠãæè¯ã«å®æœããããïŒçš®ã®åå¿ç©éã®ã¢ã«æ¯
ã¯åå¿ç©ã®æ§è³ªã«ããå€åãããæ®éïŒã¢ã«ã®ã€
ãœããµãŸãŒã«åœãïŒã¢ã«ããéå°ãªïŒã¢ã«ãŸã§ã®
ç°åŒã±ãã³ãè¯å¥œãªçµæãäžãããåå¿æéã¯åº
ãç¯å²å ã§å€åããããã¯å€§éšå䜿çšæž©åºŠã«äŸå
ããŠãããããå Žåã«ã¯å®å šãªåå¿ãåŸãã«ã¯ïŒ
ãïŒæéã§å åã§ããããããå Žåã«ã¯24ã36æ
éãé©åœã§ããã ååç©ããäœçŽã¢ã«ãã«ã€ãœã·ã¢ããŒãã§åŠ
çãããšãã€ãœããµãŸãŒã«ãïŒïŒïŒâïœãâããª
ãã³ïŒ¶ãäžãããããã¢ã«ã«ãªæ°ŽçŽ åç©åã³æ¬¡ã«
ã¢ã«ãã«åå€ã§åŠçãããšãâåã³ïŒ®â眮æã
ããã€ãœããµãŸãâãïŒïŒïŒâïœãâããªãžã³é¡
åã³ãäžããã ãããã®å šãŠã®åŒäžãïŒR1åã³R2ã¯äžèšã®
æå³ãæããããããšã¯å¯Ÿç §çã«ãR3ã¯æ°ŽçŽ ã
äœçŽã¢ã«ãã«ãããããã·âäœçŽã¢ã«ãã«åã³ã
ã³ãžã«ã ããè¡šãããã®ãžã®è»¢åã¯ã溶åªãš
ããŠäŸãã°ããªãšãã«ã¢ãã³ãŸãã¯ããªãžã³ã®åŠ
ã第äžçŽå¡©åºã䜿çšããŠãäœçŽã¢ã«ãã«ã€ãœã·
ã¢ããŒããšå ±ã«æº¶åªã®æ²žéš°æž©åºŠã«ãããŠïŒãïŒæ
éã«ãã€ãŠå ç±ããããšã«ããæè¯ã«å®æœãã
ããäžéçæç©ã§ããå°¿çŽ ãåå¿äžã«çæãã
ããåŸã ã«ããã¯ãé«åçã§äžããã ãåã³ã®æ··åç©ã«è»¢åãããããã«ã¯ã
ååç©ãæåã«ç¡æ°Žæº¶åªäžã§æ°ŽçŽ åãããªãŠã
ã§åŠçããŠãããªãŠã å¡©ãåŸãŠããããåã溶åª
äžã§ã40ã80âã«ïŒãïŒæéå ç±ãããååç©
åã³ãåå¿æ¡ä»¶ã«ããå¯å€æ§ã§ããçžäºæ¯ã§ç
æãããå Žåæ¯ã«æé©ãªåå¿æ¡ä»¶ãéžæããããš
ã«ãããåå¿ããŸãã¯ã®å¥œãŸããçææ¹åã«
åããããšã倧äœå¯èœã§ããã R3ããããŒäœçŽã¢ã«ãã«ãŸãã¯ã¢ããâäœçŽ
ã¢ã«ãã«ãæå³ããããã§ã¢ããçªçŽ ããžã¢ã«ã
ã«çœ®æãããŠããŠããããŸãã¯é£œåè€çŽ ç°åŒç°äž
ã«å«ãŸããŠããŠããããããªåŒã®ååç©ãåžæ
ãããšãã«ã¯ãR3ãããããã·âäœçŽã¢ã«ãã«
ãæå³ããäžèšãããã¯ååç©ãŸãã¯ããã
ã®æ··åç©ãæåã«å¯Ÿå¿ãããããŒäœçŽã¢ã«ãã«èª
å°äœã«è»¢åãããããŠãããã®åŸè ã¯åœæè¡ã®å š
ãŠã®å°é家ã«è¯ãç¥ãããŠããæ¹æ³ã«ããã¢ãã
âäœçŽã¢ã«ãã«èªå°äœã«è»¢åãããããã®åå¿æ®µ
éã®åºçºååç©ãšããŠã®ååç©ã®äœ¿çšã¯ãç°åŒ
äžéçæç©ã®çæã«ããé žçŽ ããçªçŽ ååãžã®ã¯
ããâäœçŽã¢ã«ãã«åºã®è»¢äœãå å«ããŠããã ãããã®å Žåã«ãããã«ããæçµååç©ã¯è€çŽ
ç°åŒçªçŽ ååãšçµåãããŠãã眮æåºR3ãæã
ããå®éçã«ã¯ãR3ãããããã·âäœçŽã¢ã«ã
ã«åºã§ããååç©ãããã¯ååç©ãŸãã¯ãã
ãã®æ··åç©é¡ãäŸãã°C1ãC4ããã²ã³åçåæ°Ž
çŽ ã®åŠãé©åœãªææ©æº¶åªäžã«æº¶è§£ãŸãã¯æžæ¿ã
ãããããŠïŒã¢ã«ããéå°éã®ã奜é©ã«ã¯çŽïŒã
çŽïŒã¢ã«åœéã®ãããã²ã³åå€ãå ãããå®è³ªç
ã«å šãŠã®äžè¬çããã²ã³åå€ã¯æºè¶³ã®ããããã«
äœçšããããããã²ã³åããªãã«ãäŸãã°å¡©åã
ãªãã«ãŸãã¯èåããªãã«ãã宀枩ãšçŽ70âãšã®
éã®ç¯å²å ã®äœçŽã§äœ¿çšããããšã«ããæè¯ã®çµ
æãæ®éåŸããããããŠããã¯ïŒãïŒæéå ã«å®
äºããã 次ã«ã¢ããâäœçŽã¢ã«ãã«èªå°äœé¡ãæçœãªå·¥
çšã«ãããäŸãã°ã¯ããã¢ã«ãã«èªå°äœãåœæè¡
ã®å šãŠã®å°é家ã«ãšã€ãŠäžè¬çã«å ¬ç¥ã§ãããã
ãŠå®æœäŸããæçœã§ããæ¡ä»¶äžã§ãå¡©åºã§åŠçã
ãããšã«ããã補é ãããäžèšã®åŠããæ¬çºæã®
ååç©é¡ã¯èå³ããCNSâæå¶ãæäžå®åã³æ
çç掻æ§ãæãããããã«ããããã¯äžè¬ã«ãã
ã®LD50å€ãããã«ããºããžã®è ¹è å æäžæã«ã¯
500mgïŒKgããé«ããããŠçµå£çæäžæã«ã¯ãã€
ãã«1000mgïŒKgããäœããªãããçžåœäœãæ¯æ§ã
æãããæçç掻æ§ã¯ããºãäžã§ã®âã«ã©ã²ãšã
ã³èªçºæ§æµ®è «è©Šéšâã«ãã確ãããããããã®ã
ããªè©Šéšã¯C.A.ãŠã€ã³ã¿ãŒïŒWinterïŒä»èã
Proc.Soc.Exptl.Biol.Med.111ïŒ544ïŒ1962ã«ãã
æå±ãããŠããæäœåŒã«åŸã€ãŠè¡ãªããããããŠ
å®æœäŸ5aïŒ21ïŒ22åã³24ã®ååç©é¡ïŒïŒ®âç°æ§
äœé¡ïŒã®LD50å€ã®çŽ1/5ãçŽ1/10ã®éã®çµå£æäž
éãå¯Ÿç §çšã«æ¯ã¹ãŠ35ïŒ ä»¥äžã®æµ®è «ã®çžåœãªæžå°
ãçãåŸããšããããšãèŠåºãããã CNSâæå¶æŽ»æ§ã¯S.ã¢ãŒãŠã€ã³ïŒIrwinïŒèã
PsychopharmacologiaïŒBarl.ïŒ13ïŒ222â257ïŒ
1968äžã«èšãããŠããåŠãäžè¬ç粟ç¥ç©çåŠçäº
æ€æ¹æ³ã«ããè©Šéšããããç¹ã«ãããã«ããºãã«
察ããŠå®æœãããããã€ãã®ä»£è¡šçå®éšã¯ãçŽïŒ
ãçŽ100mgïŒKgè ¹è å ã®ååç©ã®éãç¬éç掻æ§
åã³çèç·åŒµã®æå¶ã«æå¹ã§ããããçŽ30ãçŽ
300mgïŒKgè ¹è å ã®éã¯ç 究宀åç©ã®éåå ±èª¿å
ã³æ£ååå°ãçžåœæãªãããšã瀺ããŠããã äžèšã®èŠçŽ ãçŽæ¥é®æãå¬ç åã³çåŒç·©ã«é¢é£
ããŠããããšã«æ³šæãã¹ãã§ãããæ¬çºæã®åå
ç©ã®æäžå®æŽ»æ§ã¯G.ãããã€ïŒMaffiiïŒèã
Journ.Pharm.Pharmacol.11ïŒ129ïŒ1959äžã«èš
èŒãããŠããåŠãããŠå®æœããããâæ±ç»ãåé¿
è©Šéšâã«ããè©Šéšãããããã§ã¯æ¡ä»¶ã¥ãåç©
ïŒäžè¬ã«ããºãïŒãæ¡ä»¶è§£é€ãããªãã¡é©åœéã®
è©Šéšããããšããååç©ã®æäžã«ããããã®éåžž
ã®ç²Ÿç¥è¡åã«ããããG.ãããã€ã«åŸããšãäž»
æ¡ä»¶ã¥ãå¿çïŒCRïŒãšæ¡ä»¶ã¥ããããŠããªãå¿
çïŒURïŒã®åææå¶ãªãã®ãããªãã¡äž»æ¡ä»¶ã¥
ãå¿çãšæ¡ä»¶ã¥ããããŠããªãå¿çïŒURïŒã®æ
å³ã®ãªãæå¶ãšçµåããå¯æ¡ä»¶ã¥ãå¿çïŒCR1ïŒ
ã®æå¶ã¯æäžå®å¹æã®æçœãªæ瀺ã§ããããã®ç
ç±ã¯ãããã®æåŸã®ïŒåã®èŠçŽ ã¯é®éåã³å¬ç æ§
ã«é¢é£ããŠããããã§ããã 10å¹ã®ããºã矀ã«å¯ŸããŠå®æœããã代衚çå®éš
ã¯ãå®æœäŸ1bïŒ4aïŒ12aïŒ25ïŒïœâç°æ§äœïŒåã³
41ïŒïœâç°æ§äœïŒã®ååç©é¡ã®çŽ15ãçŽ60mgïŒKg
ã®äœéã«å€åããè ¹è å æäžãããæäžéã¯CR2
âèŠçŽ ã®æå¶ã«éåžžã«æå¹ã§ãããããŠåæã«
CRåã³URã«å¯ŸããŠå®éçã«åœ±é¿ãæããªãã
ãšã瀺ããŠããã æ¬çºæã®ååç©é¡ã¯ç°ãªãçµè·¯ã«ããæäžã§ã
ãã奜é©ãªæäžçµè·¯ã¯çµå£çåã³çŽè žå æäžã§
ããéçµå£æäžã䜿çšã§ãããçµå£çæäžçšã«
ã¯ãååç©é¡ã補è¬åŠçæäžåœ¢ãäŸãã°é å€ãã«
ãã»ã«ããšãªãã·ã«ã溶液ãªã©ãã«ãããæäžå
äœã¯æ®éã®è³Šåœ¢è¬ãäŸãã°ã§ãã·ãããŽã ãèèª
é žé¡ãã¢ã«ã³ãŒã«é¡ãç³é¡ãªã©ããå«æã§ããã
çŽè žå æäžçšã«ã¯ãååç©é¡ã¯äžè¬ç賊圢è¬ãäŸ
ãã°ã³ã³ã¢ãã¿ãŒãã¯ãã¯ã¹ã鯚ãããŸãã¯ããª
ãªãã·ãšãã¬ã³ã°ãªã³ãŒã«é¡åã³ãããã®èªå°äœ
é¡ããšæ··åãããåè¬ã®åœ¢ã§æäžãããã æäžéç¯å²ã¯ïŒæ¥åœãçŽ0.05ãçŽ200ïœã§ããã
ããã¯å¥œé©ã«ã¯åå²æäžã§æäžãããã åŸã€ãŠãæ¬çºæã¯æŽ»æ§æåãšããŠã®æ¬çºæã®å
åç©ã補è¬åŠçã«èªå®¹ã§ããæ äœãšäžç·ã«å«æã
ãŠããæ²»ççšçµæç©ãæäŸãããã®ã§ããã äžèšã®è¿œå èšèŒåã³å®æœäŸã¯ããã«æ¬çºæã説
æãããã®ã§ãããããŠããã®è£œé åã³äœ¿çšæ¹æ³
ã¯åœæè¡ã®å°é家ãå®è¡ã§ãããã®ã§ããã以äž
ã«æ¬çºæãå®æœããããã®çºæè çã«ããæå³ã
ããæè¯ã®åœ¢æ ã瀺ãã å®æœäŸ ïŒ ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«ã€
ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³â
ïŒïŒïŒšïŒâãªã³ ïœïŒ ïŒâã¢ããâïŒâã¡ãã«ã€ãœããµãŸãŒã«
ïŒ17ïœïŒã®é ¢é žïŒ170mlïŒäžæº¶æ¶²ã«35mlã®ã·ã¯ã
ãããµãã³ãå ãããããŠæ··åç©ã70âã«17æ
éå ç±ãããé ¢é žãç空äžã§èžçé€å»ããæ®æž£
ãé ¢é žãšãã«äžã«æº¶è§£ããã溶液ãçé žæ°ŽçŽ ã
ããªãŠã ã®é£œå氎溶液åã³æ¬¡ã«æ°Žã§æŽæµããç¡
æ°Žç¡«é žãããªãŠã äžã§ä¹Ÿç¥ããããŠèžçºä¹Ÿåºã
ããç²è£œçæç©ããã®ãŸãŸæ¬¡ã®æ®µéçšã«äœ¿çšã§
ãããããã¯SiO2äžã®ã¯ãããã°ã©ãã€åã³
ïœâãããµã³ïŒé ¢é žãšãã«ã®ïŒïŒïŒæ··åç©ãçš
ãã溶åºã«ããåŸããããåé26ïœïŒ84ïŒ ïŒã®
ïŒâïŒïŒâã·ã¯ãããã»ã³âïŒâã€ã«ïŒâïŒâã¡
ãã«âïŒâã€ãœããµãŸãŒã«ã¢ãã³ïŒãžãšãã«ãš
ãŒãã«ããïŒãèç¹48âã ïœïŒ ç²è£œïŒâïŒïŒâã·ã¯ãããã»ã³âïŒâã€ã«ïŒ
âïŒâã¡ãã«âïŒâã€ãœããµãŸãŒã«ã¢ãã³
ïŒ9.5ïœïŒã95mlã®ããªãžã³åã³15.8mlã®ãšãã«
ã€ãœã·ã¢ããŒãã®æ··åç©ãïŒæééæµããã次
ã«æº¶åªãç空äžã§èžçé€å»ãããæ®æž£ãïŒãïŒ
mlã®é ¢é žãšãã«ãšå ±ã«æ°åééæµããããããŠ
çæããçŽç²ãªïŒïŒïŒïŒïŒïŒïŒâããã©ããã
âïŒâã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâ
ã€ãœãããªã³âïŒïŒ4HïŒâãªã³ããã€ã«ã¿ãŒäž
ã§éãããããŠä¹Ÿç¥ããããžã¡ãã«ãã«ã ã¢ã
ãïŒã¡ã¿ããŒã«ããã®åçµæ¶ååŸã«ãçæç©ã¯
èç¹255âãæããŠãããçŽç²ãªäžéçæç©ã
ãåºçºãããšãã«ã¯ãäžéçæç©ã«å¯ŸããŠèšç®
ããŠ88ã92ïŒ ã®åçãåŸãããã å®æœäŸ ïŒã14 ïœïŒ ã€ãœããµãŸãŒã«ã¢ãã³é¡ åŒã®ãªããµãŸãŒã«ã¢ãã³åã³åŒã®ã±ãã³ã
ãåºçºãããšãå®æœäŸ1aïŒã«èšãããŠããæ¹æ³
ãšå®è³ªçã«åäžã®æ¹æ³ã«ããäžèšã®åŒã®ååç©
é¡ã補é ãããã
ãè¡šã
ïœïŒ ã€ãœããµãŸãŒã«âã€ãœãããªã³é¡
äžèšã§åŸãããã€ãœããµãŸãŒã«ã¢ãã³é¡ãã
åºçºããããŠå®è³ªçã«å®æœäŸ1bïŒã«èšãããŠã
ãåŠãè¡ãªããšãäžèšã®åŒã®ååç©é¡ã補é ã
ããã
åºçºããããŠå®è³ªçã«å®æœäŸ1bïŒã«èšãããŠã
ãåŠãè¡ãªããšãäžèšã®åŒã®ååç©é¡ã補é ã
ããã
ãè¡šã
å®æœäŸ 15
ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«â
ïŒâããããã·ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœã
âã€ãœãããªã³åã³ïŒïŒïŒïŒïŒïŒïŒâããã©ã
ããâïŒâã¡ãã«âïŒâãããã«ã€ãœããµãŸãŒ
ã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâ
ãªã³ã 22.5ïœã®ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâ
ã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãã
ãªã³âïŒïŒ4HïŒâãªã³ã®ç¡æ°Žãžã¡ãã«ãã«ã ã¢ã
ãïŒ600mlïŒäžã®æ¹æãããŠããæžæ¿æ¶²ã«ã5.81
ïœã®æ°ŽçŽ åãããªãŠã ã®é±æ²¹äž50ïŒ æžæ¿æ¶²ãå°éš
åãã€20âã«ãããŠçªçŽ é°å²æ°äžã§å ãããæ··å
ç©ã70âã§ïŒæéå ç±ãã次ã«150âã«å·åŽãã
ãããŠ50mlã®ãžã¡ãã«ãã«ã ã¢ããäžã®15mlã®è
åãããã«ã滎äžãããå ç±ã70âã§2.5æéç¶
ãã溶åªãç空äžã§èžçºããããããŠæ®æž£ãå¡©å
ã¡ãã¬ã³åã³æ°Žã§æŽæµãããææ©å±€ãåé¢ããæ°Ž
å±€ãå¡©åã¡ãã¬ã³ã§æŽæµãããããŠäžç·ã«ããæ
æ©å±€ãäžæ§åå¿ãšãªããŸã§æŽæµããã溶åªãç空
äžã§èžçºããããçæããç°æ§äœæ··åç©ïŒ26ïœïŒ
ãã·ãªã«ã²ã«ïŒ400ïœïŒäžã®ã¯ãããã°ã©ãã€ãš
å¡©åã¡ãã¬ã³åã³é ¢é žãšãã«ãçšãã溶åºã«ãã
åé¢ããã極æ§ã®æ¯èŒçå°ããçæç©ãããªãã¡
ïŒâããããã·èªå°äœã¯ããšãã«ãšãŒãã«ïŒãã
ãµã³ããçµæ¶åããããšãã«ãèç¹97ã98âãæ
ããŠãããåé12.3ïœãæ¯èŒç極æ§ã®å€§ããçæ
ç©ãããªãã¡ïŒâãããã«èªå°äœãã¯ãšãã«ãšãŒ
ãã«ïŒãããµã³ããçµæ¶åããããšãã«èç¹82ã
83âãæããŠãããåé11.8ïœã å®æœäŸ 16ã44 å®æœäŸ15ãšå®è³ªçã«åäžã®æ¹æ³ã«ããäžèšã®åŒ
åã³ã®ååç©é¡ã補é ãããã
ïŒâããããã·ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœã
âã€ãœãããªã³åã³ïŒïŒïŒïŒïŒïŒïŒâããã©ã
ããâïŒâã¡ãã«âïŒâãããã«ã€ãœããµãŸãŒ
ã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâ
ãªã³ã 22.5ïœã®ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâ
ã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãã
ãªã³âïŒïŒ4HïŒâãªã³ã®ç¡æ°Žãžã¡ãã«ãã«ã ã¢ã
ãïŒ600mlïŒäžã®æ¹æãããŠããæžæ¿æ¶²ã«ã5.81
ïœã®æ°ŽçŽ åãããªãŠã ã®é±æ²¹äž50ïŒ æžæ¿æ¶²ãå°éš
åãã€20âã«ãããŠçªçŽ é°å²æ°äžã§å ãããæ··å
ç©ã70âã§ïŒæéå ç±ãã次ã«150âã«å·åŽãã
ãããŠ50mlã®ãžã¡ãã«ãã«ã ã¢ããäžã®15mlã®è
åãããã«ã滎äžãããå ç±ã70âã§2.5æéç¶
ãã溶åªãç空äžã§èžçºããããããŠæ®æž£ãå¡©å
ã¡ãã¬ã³åã³æ°Žã§æŽæµãããææ©å±€ãåé¢ããæ°Ž
å±€ãå¡©åã¡ãã¬ã³ã§æŽæµãããããŠäžç·ã«ããæ
æ©å±€ãäžæ§åå¿ãšãªããŸã§æŽæµããã溶åªãç空
äžã§èžçºããããçæããç°æ§äœæ··åç©ïŒ26ïœïŒ
ãã·ãªã«ã²ã«ïŒ400ïœïŒäžã®ã¯ãããã°ã©ãã€ãš
å¡©åã¡ãã¬ã³åã³é ¢é žãšãã«ãçšãã溶åºã«ãã
åé¢ããã極æ§ã®æ¯èŒçå°ããçæç©ãããªãã¡
ïŒâããããã·èªå°äœã¯ããšãã«ãšãŒãã«ïŒãã
ãµã³ããçµæ¶åããããšãã«ãèç¹97ã98âãæ
ããŠãããåé12.3ïœãæ¯èŒç極æ§ã®å€§ããçæ
ç©ãããªãã¡ïŒâãããã«èªå°äœãã¯ãšãã«ãšãŒ
ãã«ïŒãããµã³ããçµæ¶åããããšãã«èç¹82ã
83âãæããŠãããåé11.8ïœã å®æœäŸ 16ã44 å®æœäŸ15ãšå®è³ªçã«åäžã®æ¹æ³ã«ããäžèšã®åŒ
åã³ã®ååç©é¡ã補é ãããã
ãè¡šã
ãè¡šã
ãè¡šã
該工çšã®å¯èœãªå€æ³ãããè¯ã説æãããã
ã«ãå®æœäŸ24ã以äžã«å®å šã«èšèŒããã20.4ïœã®
å®æœäŸ1bã«åŸã€ãŠè£œé ãããïŒïŒïŒïŒïŒïŒïŒâ
ããã©ãããâïŒâã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒ
ïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâãªã³ã®550ml
ã®ç¡æ°Žãžã¡ãã«ãã«ã ã¢ããäžã®æ¹æãããŠãã
æžæ¿æ¶²ã«ã3.3ïœã®æ°ŽçŽ åãããªãŠã 80ïŒ æžæ¿æ¶²
ã20âã«ãããŠçªçŽ äžã§å°ééšåãã€å ããã70
âã§ïŒæéå ç±ããåŸã«ãæ··åç©ã15âã«å·åŽ
ãããããŠ50mlã®ãžã¡ãã«ãã«ã ã¢ããäžã®ïŒml
ã®ïŒâããã¢ãšã¿ããŒã«ã滎äžãããæ··åç©ã70
âã«ïŒæéå ç±ãã溶åªãç空äžã§èžçºãããã
ããŠæ®æž£ãå¡©åã¡ãã¬ã³ã§æœåºãããææ©æº¶åªã
æ°Žã§æŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãããããŠ
ç空äžã§èžçºä¹Ÿåºãããæ®æž£ãé ¢é žãšãã«ããå
çµæ¶åãããããšã«ããïŒïœã®ïŒïŒïŒïŒïŒïŒïŒâ
ããã©ãããâïŒâã¡ãã«âïŒâããããã·ãšã
ã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³
âïŒïŒ4HïŒâãªã³ãåŸããããèç¹163ã164âã æ¯æ¶²ãã400ïœã®ã·ãªã«ã²ã«äžã§ã¯ãããã°ã©
ãã€äžŠã³ã«ãããµã³åã³é ¢é žãšãã«ãçšãã溶åº
ã«ãããïŒïœã®ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâ
ïŒâã¡ãã«âïŒâïŒïŒâããããã·ãšããã·ïŒâã€
ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒ
ïŒ4HïŒâãªã³ãåŸããããèç¹157â159âã å¥ã®çŸ€ã®ïŒâããããã·ãšãã«èªå°äœïŒ6.7ïœïŒ
ãã¯ãããã°ã©ãã€ã®æåŸã®çåããåŸãããã å®æœäŸ 45 ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«â
ïŒâïŒïŒâã¯ãããšãã«ïŒâã€ãœããµãŸãŒã«â
ãïŒïŒïŒâïœãâã€ãœãµããªã³âïŒïŒ4HïŒâãªã³ã 12ïœã®å®æœäŸ24ã«åŸã€ãŠåŸãããïŒçš®ã®ç°æ§äœ
é¡ã®åé¢åã®æ··åç©ã®200mlã®å¡©åã¡ãã¬ã³äžã®
ïŒâã«å·åŽãããŠããæ¹æãããŠãã溶液ã«ã
6.96mlã®å¡©åããªãã«ã®30mlã®å¡©åã¡ãã¬ã³äžæº¶
液ã滎ã æ·»å ããã20âã«ãããïŒæéåŸã«ã溶
åªãç空äžã§é€å»ãããããŠãžãšãã«ãšãŒãã«ã
æ®æž£ã«å ãããåºäœãéãããšãããã¯å®è³ªçã«
çŽç²ãªïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ã
ã«âïŒâïŒïŒâã¯ãããšãã«ïŒâã€ãœããµãŸãŒã«â
ãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâãªã³ã§
ãã€ããåé12ïœïŒ94ïŒ ïŒãåæçã«çŽç²ãªè©Šæ
ãé ¢é žãšãã«ããåçµæ¶åã«ããåŸããããèç¹
161ã162âã å®æœäŸ 46ã50 å®æœäŸ45ãšå®è³ªçã«åãæ¹æ³ã«ãããäžèšã®åŒ
ã®ååç©é¡ã補é ãããã
ã«ãå®æœäŸ24ã以äžã«å®å šã«èšèŒããã20.4ïœã®
å®æœäŸ1bã«åŸã€ãŠè£œé ãããïŒïŒïŒïŒïŒïŒïŒâ
ããã©ãããâïŒâã¡ãã«ã€ãœããµãŸãŒã«âãïŒïŒ
ïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâãªã³ã®550ml
ã®ç¡æ°Žãžã¡ãã«ãã«ã ã¢ããäžã®æ¹æãããŠãã
æžæ¿æ¶²ã«ã3.3ïœã®æ°ŽçŽ åãããªãŠã 80ïŒ æžæ¿æ¶²
ã20âã«ãããŠçªçŽ äžã§å°ééšåãã€å ããã70
âã§ïŒæéå ç±ããåŸã«ãæ··åç©ã15âã«å·åŽ
ãããããŠ50mlã®ãžã¡ãã«ãã«ã ã¢ããäžã®ïŒml
ã®ïŒâããã¢ãšã¿ããŒã«ã滎äžãããæ··åç©ã70
âã«ïŒæéå ç±ãã溶åªãç空äžã§èžçºãããã
ããŠæ®æž£ãå¡©åã¡ãã¬ã³ã§æœåºãããææ©æº¶åªã
æ°Žã§æŽæµããç¡«é žãããªãŠã äžã§ä¹Ÿç¥ãããããŠ
ç空äžã§èžçºä¹Ÿåºãããæ®æž£ãé ¢é žãšãã«ããå
çµæ¶åãããããšã«ããïŒïœã®ïŒïŒïŒïŒïŒïŒïŒâ
ããã©ãããâïŒâã¡ãã«âïŒâããããã·ãšã
ã«ã€ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³
âïŒïŒ4HïŒâãªã³ãåŸããããèç¹163ã164âã æ¯æ¶²ãã400ïœã®ã·ãªã«ã²ã«äžã§ã¯ãããã°ã©
ãã€äžŠã³ã«ãããµã³åã³é ¢é žãšãã«ãçšãã溶åº
ã«ãããïŒïœã®ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâ
ïŒâã¡ãã«âïŒâïŒïŒâããããã·ãšããã·ïŒâã€
ãœããµãŸãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒ
ïŒ4HïŒâãªã³ãåŸããããèç¹157â159âã å¥ã®çŸ€ã®ïŒâããããã·ãšãã«èªå°äœïŒ6.7ïœïŒ
ãã¯ãããã°ã©ãã€ã®æåŸã®çåããåŸãããã å®æœäŸ 45 ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«â
ïŒâïŒïŒâã¯ãããšãã«ïŒâã€ãœããµãŸãŒã«â
ãïŒïŒïŒâïœãâã€ãœãµããªã³âïŒïŒ4HïŒâãªã³ã 12ïœã®å®æœäŸ24ã«åŸã€ãŠåŸãããïŒçš®ã®ç°æ§äœ
é¡ã®åé¢åã®æ··åç©ã®200mlã®å¡©åã¡ãã¬ã³äžã®
ïŒâã«å·åŽãããŠããæ¹æãããŠãã溶液ã«ã
6.96mlã®å¡©åããªãã«ã®30mlã®å¡©åã¡ãã¬ã³äžæº¶
液ã滎ã æ·»å ããã20âã«ãããïŒæéåŸã«ã溶
åªãç空äžã§é€å»ãããããŠãžãšãã«ãšãŒãã«ã
æ®æž£ã«å ãããåºäœãéãããšãããã¯å®è³ªçã«
çŽç²ãªïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ã
ã«âïŒâïŒïŒâã¯ãããšãã«ïŒâã€ãœããµãŸãŒã«â
ãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâãªã³ã§
ãã€ããåé12ïœïŒ94ïŒ ïŒãåæçã«çŽç²ãªè©Šæ
ãé ¢é žãšãã«ããåçµæ¶åã«ããåŸããããèç¹
161ã162âã å®æœäŸ 46ã50 å®æœäŸ45ãšå®è³ªçã«åãæ¹æ³ã«ãããäžèšã®åŒ
ã®ååç©é¡ã補é ãããã
ãè¡šã
å®æœäŸ 51
ïŒïŒïŒïŒïŒïŒïŒâããã©ãããâïŒâã¡ãã«â
ïŒâãïŒâïŒïŒâã¢ã«ããªããšãã«ïŒãâã€ãœããµãŸ
ãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâ
ãªã³ã ïŒïœã®å®æœäŸ45ã«åŸã€ãŠè£œé ãããâã¯ãã
ãšãã«ååç©ã®35mlã®ã¢ã«ããªã³äžæžæ¿æ¶²ãçªçŽ
äžã§1.5æééæµããããéå°ã®ã¢ã«ããªã³ãç
空äžã§èžçé€å»ããåŸã«ãé ¢é žãšãã«ãæ®æž£ã«å
ããææ©æº¶æ¶²ãæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããããŠç空äžã§èžçºä¹Ÿåºããã140ïœã®
ã·ãªã«ã²ã«äžã§ã®ã¯ãããã°ã©ãã€åã³ãããµ
ã³ïŒé ¢é žãšãã«ã®ïŒïŒïŒæ··åç©ãçšãã溶åºã«ã
ããæšèšã®ååç©ãåŸããããåé4.8ïœïŒ54
ïŒ ïŒã ææ©æº¶æ¶²ããå¡©åæ°ŽçŽ ãçšããŠæ²æ®¿ãããããš
ã«ããæ®é補é ãããå¡©é žå¡©ã¯ããšã¿ããŒã«ãã
åçµæ¶åããããšãã«ã¯ãèç¹190âïŒå解ïŒã
æããŠããã å®æœäŸ 52ã56 å®æœäŸ51ã®æº¶åªïŒè©Šè¬ã¢ã«ããªã³ã®ä»£ãã«å Žå
ã«ãããšã¿ããŒã«ãŸãã¯ãžã¡ãã«ãã«ã ã¢ããã®
åŠã溶åªã䜿çšããããšä»¥å€ã¯å®æœäŸ51ãšå®è³ªç
ã«åãæ¹æ³ã«ãããäžèšã®åŒã®ååç©é¡ã補é
ãããã
ïŒâãïŒâïŒïŒâã¢ã«ããªããšãã«ïŒãâã€ãœããµãŸ
ãŒã«âãïŒïŒïŒâïœãâã€ãœãããªã³âïŒïŒ4HïŒâ
ãªã³ã ïŒïœã®å®æœäŸ45ã«åŸã€ãŠè£œé ãããâã¯ãã
ãšãã«ååç©ã®35mlã®ã¢ã«ããªã³äžæžæ¿æ¶²ãçªçŽ
äžã§1.5æééæµããããéå°ã®ã¢ã«ããªã³ãç
空äžã§èžçé€å»ããåŸã«ãé ¢é žãšãã«ãæ®æž£ã«å
ããææ©æº¶æ¶²ãæ°Žã§æŽæµããç¡«é žãããªãŠã äžã§
也ç¥ãããããŠç空äžã§èžçºä¹Ÿåºããã140ïœã®
ã·ãªã«ã²ã«äžã§ã®ã¯ãããã°ã©ãã€åã³ãããµ
ã³ïŒé ¢é žãšãã«ã®ïŒïŒïŒæ··åç©ãçšãã溶åºã«ã
ããæšèšã®ååç©ãåŸããããåé4.8ïœïŒ54
ïŒ ïŒã ææ©æº¶æ¶²ããå¡©åæ°ŽçŽ ãçšããŠæ²æ®¿ãããããš
ã«ããæ®é補é ãããå¡©é žå¡©ã¯ããšã¿ããŒã«ãã
åçµæ¶åããããšãã«ã¯ãèç¹190âïŒå解ïŒã
æããŠããã å®æœäŸ 52ã56 å®æœäŸ51ã®æº¶åªïŒè©Šè¬ã¢ã«ããªã³ã®ä»£ãã«å Žå
ã«ãããšã¿ããŒã«ãŸãã¯ãžã¡ãã«ãã«ã ã¢ããã®
åŠã溶åªã䜿çšããããšä»¥å€ã¯å®æœäŸ51ãšå®è³ªç
ã«åãæ¹æ³ã«ãããäžèšã®åŒã®ååç©é¡ã補é
ãããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒ ïŒ»åŒäžãã¯ççŽ æ°ãïŒãïŒã®äœçŽã¢ã«ãã«ãŸ
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ
R1ïŒR2ã¯ã¢ã«ãã¬ã³åºâïŒCH2ïŒïœâãè¡šããã
ããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããããããŠãããã®
ã¡ãã¬ã³åºã®ïŒã€ã¯åºãåŒãã«ãã眮ãæã ãããŠããŠããããããã§R6ã¯äœçŽã¢ã«ãã«ã
äœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢ã«ã³ãã·ïŒã«ã«
ããã«ãè¡šããïŒ R3ã¯ïŒåã ãååšããŠãããããŠæ°ŽçŽ ãäœçŽ
ã¢ã«ãã«ãããããã·âäœçŽã¢ã«ãã«ããã³ãžã«
ãè¡šããããããŠãããè€çŽ ç°åŒçªçŽ ãšçµåããŠ
ããå Žåã«ã¯ãã®ã¢ãã³çªçŽ ããžã¢ã«ãã«çœ®æã
ããŠããŠããããããã¯é£œåè€çŽ ç°åŒç°äžã«å å«
ãããŠããŠããããããŒäœçŽã¢ã«ãã«ãŸãã¯ã¢ã
ãâäœçŽã¢ã«ãã«ããè¡šããïŒ ç¹ç·ã¯äºéçµåãè€çŽ ç°åŒçªçŽ ååãšççŽ åå
ãšã®éãŸãã¯é žçŽ ãšççŽ ååãšã®éã®ããããã«
ååšããŠããããšã瀺ããŠããã第äžã®å Žåã«ã¯
åºR3ã¯é žçŽ ãšçµåããŠããã第äºã®å Žåã«ã¯çª
çŽ ååãšçµåããŠãã ã®ã€ãœããµãŸãŒã«ïŒ»ïŒïŒïŒâïœïŒœããªãžã³é¡ã ïŒ åŒ ïŒ»åŒäžãã¯ççŽ æ°ãïŒãïŒã®äœçŽã¢ã«ãã«ãŸ
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ
R1åã³R2ã¯äžç·ã«ãªã€ãŠã¢ã«ãã¬ã³åºâïŒCH2ïŒ
ïœâãè¡šãããããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããã
ãããŠãããã®ã¡ãã¬ã³åºã®ïŒã€ã¯åºãåŒã ã«ãã眮ãæããããŠããŠããããããã§R6ã¯
äœçŽã¢ã«ãã«ãäœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢
ã«ã³ãã·ïŒã«ã«ããã«ãè¡šããïŒ R3ã¯ïŒåã ãååšããŠãããããŠæ°ŽçŽ ãäœçŽ
ã¢ã«ãã«ãããããã·âäœçŽã¢ã«ãã«ããã³ãžã«
ãè¡šãã ã®ååç©ã®è£œé æ¹æ³ã§ãã€ãŠãåŒ ã®ååç©ãã第äžçŽå¡©åºäžã§ãäœçŽã¢ã«ãã«ã€ãœ
ã·ã¢ããŒããšå ±ã«ïŒãïŒæéã«ããã€ãŠè©²å¡©åºã®
沞隰枩床ã«å ç±ãããããŠåŸãããåŒ ã®äžéçæç©ååç©ãç¡æ°Žæº¶åªäžã§æåã¯å®€æž©ã«
ãããŠãæ°ŽçŽ ãããªãŠã ã§åŠçã次ã«åäžæº¶åªäž
ã§40ã80âã«ãããŠïŒãïŒæéã«ããã€ãŠãåŠç
ãããããŠææã«ããäœçŽã¢ã«ãã«ãã©ã€ããã
ãããã·âäœçŽã¢ã«ãã«ãã©ã€ããŸãã¯ãã³ãžã«
ãã©ã€ãã§åŠçããããšãç¹åŸŽãšããæ¹æ³ã ïŒ åŒ ïŒ»åŒäžãã¯ççŽ æ°ãïŒãïŒã®äœçŽã¢ã«ãã«ãŸ
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ
R1åã³R2ã¯äžç·ã«ãªã€ãŠã¢ã«ãã¬ã³åºâïŒCH2ïŒ
ïœâãè¡šãããããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããã
ãããŠãããã®ã¡ãã¬ã³åºã®ïŒã€ã¯åºãåŒã ã«ãã眮ãæããããŠããŠããããããã§R6ã¯
äœçŽã¢ã«ãã«ãäœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢
ã«ã³ãã·ïŒã«ã«ããã«ãè¡šããïŒ R3ã¯ãã®ã¢ãã³çªçŽ ããžã¢ã«ãã«çœ®æãããŠ
ããŠããããããã¯é£œåè€çŽ ç°åŒç°äžã«å å«ãã
ãŠããŠãããã¢ããâäœçŽã¢ã«ãã«ãè¡šãã ã®ååç©ã®è£œé æ¹æ³ã§ãã€ãŠãåŒ ïŒ»åŒäžãR4ã¯ïŒåã ãååšããŠãããããŠã
ãããã·âäœçŽã¢ã«ãã«ãè¡šããã ç¹ç·ã¯äºéçµåãè€çŽ ç°åŒçªçŽ ååãšççŽ åå
ãšã®éãŸãã¯é žçŽ ãšççŽ ååãšã®éã®ããããã«
ååšããŠããããšã瀺ããŠããã第äžã®å Žåã«ã¯
åºR4ã¯é žçŽ ãšçµåããŠããã第äºã®å Žåã«ã¯çª
çŽ ååãšçµåããŠãã ã®ååç©ãŸãã¯R4ãåãæå³ãæããïŒçš®ã®ç°
æ§äœé¡ã®æ··åç©ãã宀枩ãšçŽ70âãšã®éã®æž©åºŠã«
ãããŠãã¢ã«éå°éã®ããã²ã³å€ãšåå¿ããïŒã
ããŠåŸãããããã¢ã«ãã«èªå°äœãå ¬ç¥ã®æ¹æ³ã«
ããã¢ããã¢ã«ãã«èªå°äœã«è»¢åããããšãç¹åŸŽ
ãšããæ¹æ³ã ïŒ åŒ ïŒ»åŒäžãã¯ççŽ æ°ãïŒãïŒã®äœçŽã¢ã«ãã«ãŸ
ãã¯ããšãã«ãããã¯ããããšãã«ãè¡šããïŒ
R1ïŒR2ã¯ã¢ã«ãã¬ã³åºâïŒCH2ïŒïœâãè¡šããã
ããã§ïœã¯ïŒãïŒã®æŽæ°ã§ããããããŠãããã®
ã¡ãã¬ã³åºã®ïŒã€ã¯åºãåŒãã«ãã眮ãæã ãããŠããŠããããããã§R6ã¯äœçŽã¢ã«ãã«ã
äœçŽã¢ã«ã«ãã€ã«ãŸãã¯ïŒäœçŽã¢ã«ã³ãã·ïŒã«ã«
ããã«ãè¡šããïŒ R3ã¯ïŒåã ãååšããŠãããããŠæ°ŽçŽ ãäœçŽ
ã¢ã«ãã«ãããããã·âäœçŽã¢ã«ãã«ããã³ãžã«
ãè¡šããããããŠãããè€çŽ ç°åŒçªçŽ ãšçµåããŠ
ããå Žåã«ã¯ãã®ã¢ãã³çªçŽ ããžã¢ã«ãã«çœ®æã
ããŠããŠããããããã¯é£œåè€çŽ ç°åŒç°äžã«å å«
ãããŠããŠããããããŒäœçŽã¢ã«ãã«ãŸãã¯ã¢ã
ãâäœçŽã¢ã«ãã«ããè¡šããïŒ ç¹ç·ã¯äºéçµåãè€çŽ ç°åŒçªçŽ ååãšççŽ åå
ãšã®éãŸãã¯é žçŽ ãšççŽ ååãšã®éã®ããããã«
ååšããŠããããšã瀺ããŠããã第äžã®å Žåã«ã¯
åºR3ã¯é žçŽ ãšçµåããŠããã第äºã®å Žåã«ã¯çª
çŽ ååãšçµåããŠãã ã®ã€ãœããµãŸãŒã«ïŒ»ïŒïŒïŒâïœïŒœããªãžã³é¡ã®å°
ãªããšãïŒçš®ã掻æ§æåãšããŠå«æããŠããäžæ¢
ç¥çµæå¶å€ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8209361 | 1982-03-30 | ||
| GB8209361 | 1982-03-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58177992A JPS58177992A (ja) | 1983-10-18 |
| JPH0342276B2 true JPH0342276B2 (ja) | 1991-06-26 |
Family
ID=10529406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58050590A Granted JPS58177992A (ja) | 1982-03-30 | 1983-03-28 | ã€ãœããµãŸâã«âãïŒïŒïŒâïœãâããªãžã³é¡ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4530927A (ja) |
| EP (1) | EP0090275B1 (ja) |
| JP (1) | JPS58177992A (ja) |
| AT (1) | ATE30425T1 (ja) |
| AU (1) | AU561013B2 (ja) |
| CA (1) | CA1204440A (ja) |
| DE (1) | DE3374199D1 (ja) |
| DK (1) | DK143583A (ja) |
| ES (1) | ES521083A0 (ja) |
| GR (1) | GR77945B (ja) |
| IL (1) | IL68171A (ja) |
| PH (1) | PH18337A (ja) |
| ZA (1) | ZA831738B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2161667B (en) * | 1984-07-12 | 1988-04-27 | John Spencer Liggett | Portable facial image synthesiser |
| JPH04368375A (ja) * | 1991-06-17 | 1992-12-21 | Otsuka Pharmaceut Factory Inc | ã€ãœãªããµãŸãŒã«èªå°äœ |
| WO1997001555A1 (en) * | 1995-06-29 | 1997-01-16 | Novo Nordisk A/S | Novel substituted azacyclic compounds |
| EP1408042A4 (en) * | 2001-06-14 | 2005-02-02 | Banyu Pharma Co Ltd | NOVEL ISOXAZOLOPYRIDONE DERIVATIVES AND THEIR USE |
| GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3381016A (en) * | 1966-03-04 | 1968-04-30 | Upjohn Co | Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation |
| US3541101A (en) * | 1966-03-04 | 1970-11-17 | Upjohn Co | Isoxazolo(5,4-b)pwridines,5,6 - polymethyleneisoxazolo(5,4 - b)pyridines and processes therefor |
| US3816429A (en) * | 1971-08-10 | 1974-06-11 | Ciba Geigy Corp | Tetrahydroisoxazolo(5,4-c)isoquinolines |
| IT1054655B (it) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
-
1983
- 1983-03-10 AU AU12330/83A patent/AU561013B2/en not_active Ceased
- 1983-03-10 GR GR70751A patent/GR77945B/el unknown
- 1983-03-14 ZA ZA831738A patent/ZA831738B/xx unknown
- 1983-03-14 PH PH28645A patent/PH18337A/en unknown
- 1983-03-17 DE DE8383102648T patent/DE3374199D1/de not_active Expired
- 1983-03-17 AT AT83102648T patent/ATE30425T1/de not_active IP Right Cessation
- 1983-03-17 EP EP83102648A patent/EP0090275B1/en not_active Expired
- 1983-03-18 IL IL68171A patent/IL68171A/xx unknown
- 1983-03-28 JP JP58050590A patent/JPS58177992A/ja active Granted
- 1983-03-28 US US06/479,378 patent/US4530927A/en not_active Expired - Fee Related
- 1983-03-29 CA CA000424793A patent/CA1204440A/en not_active Expired
- 1983-03-29 DK DK143583A patent/DK143583A/da not_active IP Right Cessation
- 1983-03-29 ES ES521083A patent/ES521083A0/es active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IL68171A (en) | 1986-03-31 |
| EP0090275A2 (en) | 1983-10-05 |
| ES8405407A1 (es) | 1984-06-01 |
| EP0090275B1 (en) | 1987-10-28 |
| IL68171A0 (en) | 1983-06-15 |
| CA1204440A (en) | 1986-05-13 |
| ZA831738B (en) | 1984-01-25 |
| AU1233083A (en) | 1983-10-06 |
| DK143583A (da) | 1983-10-01 |
| ES521083A0 (es) | 1984-06-01 |
| GR77945B (ja) | 1984-09-25 |
| AU561013B2 (en) | 1987-04-30 |
| EP0090275A3 (en) | 1984-05-02 |
| DK143583D0 (da) | 1983-03-29 |
| DE3374199D1 (de) | 1987-12-03 |
| US4530927A (en) | 1985-07-23 |
| ATE30425T1 (de) | 1987-11-15 |
| JPS58177992A (ja) | 1983-10-18 |
| PH18337A (en) | 1985-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2656189B2 (ja) | ãã³ãŸã€ãœãã¢ãŸãŒã«ããã³ãã³ãŸã€ãœããµãŸãŒã«âïŒâã«ã«ãããµããããã®è£œæ³ããã³ãããããªãæ粟ç¥ç å€ | |
| PL181895B1 (pl) | Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL | |
| EP0104522B1 (en) | New pyrazolo(3,4-b)pyridine derivatives and process for producing them | |
| JPH054983A (ja) | ã€ãœãããªãã³èªå°äœããã®è£œé æ¹æ³ããã³ãã®èªå°äœãæå¹æåãšããŠå«æããïŒâïœïœïŒ ã¬ã»ãã¿ãŒæ®æå€ | |
| KR20100020044A (ko) | ïœïŒ§ïœïœïŒ²ïŒ ìíê³ ëì€íž íì±ì ê°ë ììžížë ì ë첎 | |
| JPH07119213B2 (ja) | ã ã¹ã«ãªã³ãªã»ãã¿ãŒã¢ã³ã¿ãŽãã¹ã | |
| PT94070A (pt) | Processo para a preparacao de derivados de piperazina | |
| WO2001083487A1 (fr) | Derive de froindazole | |
| JP2707936B2 (ja) | βâãªããœâβâãã³ãŒã³ãããã³ããªã¢ããèªå°äœ | |
| KR830000026B1 (ko) | ížëŠ¬ì¬ìŽíŽëŠ ì€ë¥Ží -ìµí©ë í€í ë¡ì¬ìŽíŽëŠ íí©ë¬Œì ì ì¡°ë°©ë² | |
| HU203350B (en) | Process for producing antiinflammatory tricyclic oxindole derivatives | |
| JPH0342276B2 (ja) | ||
| JPH0322389B2 (ja) | ||
| JP2980749B2 (ja) | ãã©ã³èªå°äœ | |
| EP0336555A1 (en) | 4,5,6,7-Tetrahydroisothiazolo (4,5-c)pyridine derivatives and isomers | |
| JP3042915B2 (ja) | ïŒâïŒïŒïœâã€ã³ããŸãŒã«âïŒâã€ã«ïŒâïŒâããªãžã³ã¢ãã³ããã³ãã®è£œé æ³ | |
| EP0254527B1 (en) | Tetracyclic indole derivatives | |
| JPH06505698A (ja) | æ°èŠååç© | |
| EP0302787B1 (fr) | Dérivés de (pipéridinyl-4)méthyl-2 benzofuro[2,3-c]pyridines, leur préparation et leur application en thérapeutique | |
| KR830001838B1 (ko) | íë-íŽë늬ì§ëì ì ì¡°ë°©ë² | |
| JPH064637B2 (ja) | æ°èŠãªã€ã³ããŒã«èªå°äœ | |
| US5912348A (en) | Method of making arylamino triazolopyridines | |
| EP0573548B1 (en) | Neuroprotectant agents | |
| JPH04221386A (ja) | ïŒïŒšâãããïŒïŒïŒâïœïŒœããšãïŒïŒïŒâïœïŒœïŒ»ïŒïŒïŒïŒœãžã¢ãŒãã³ã®æ°èŠèªå°äœããããã®è£œé æ¹æ³åã³ããããå«æããå»è¬åçµæç© | |
| JPH03294277A (ja) | ãããªãžã³èªå°äœ |